DiaMedica Therapeutics Inc (DMAC) FinancialsDMACFinancialDiaMedica Therapeutics Inc

Evaluating the bottom line, DiaMedica Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -114.62%, provide a clear picture of how effectively DMAC converts its operational activities into shareholder value.

In the context of the broader market, DMAC competes directly with industry leaders such as SABS and AGEN. With a market capitalization of $364.00M, it holds a leading position in the sector. When comparing efficiency, DMAC's gross margin of N/A stands against SABS's N/A and AGEN's 100.00%. Such benchmarking helps identify whether DiaMedica Therapeutics Inc is trading at a premium or discount relative to its financial performance.

DMAC reported a net loss of $10.1 million in Q2 2026, which is a significant increase from the $7.7 million loss in the same quarter last year. The company's current ratio is 6.72, indicating good short-term liquidity, but the financial pressure is evident with a cash position decrease from $59.9 million to $43.5 million.